Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.

Abstract

BACKGROUND Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor in dogs. At present, conventional adjuvant chemotherapy provides only a modest survival benefit for treated dogs. Continuous oral administration of low-dose chemotherapy (LDC) has been suggested as an alternative to conventional chemotherapy protocols. Therefore, we… (More)

Topics

4 Figures and Tables

Cite this paper

@article{Lana2007ContinuousLO, title={Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.}, author={Susan E Lana and Lance U'ren and Susan Plaza and Robyn Elmslie and Daniel L. Gustafson and Paul S. Morley and Steven Dow}, journal={Journal of veterinary internal medicine}, year={2007}, volume={21 4}, pages={764-9} }